Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
Fletcher
Gerald F
GF
Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA. fletcher.gerald@mayo.edu
Bufalino
Vincent
V
Costa
Fernando
F
Goldstein
Larry B
LB
Jones
Dan
D
Smaha
Lynn
L
Smith
Sidney C
SC
Stone
Neil
N
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists; D016540:Smoking Cessation; D020521:Stroke / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000451:Mineralocorticoid Receptor Antagonists